Un groupe basé sur la complémentarité d'expertise avec un savoir-faire pluridisciplinaire

Actualité

Trail, the new Grail?

Date de publication : 20/11/2020

Diaclone has developed its TRAIL portfolio offering cytometry reagents, biologically active antibodies as well as kits for the determination of soluble forms of TRAIL and TRAIL receptors. Diaclone has been an essential support for research in this field for more than 20 years.

Interested to know what Diaclone can do for you in the TRAIL field?

An innovative target in mind? A therapeutic antibody to develop?

Read more on LinkedIn

Time to contact the Diaclone team!

  • Fière d’avoir participé au développement du vaccin contre la COVID-19
    Date de publication : 21/01/2021

    Toute l’équipe de RD-Biotech est fière d’avoir participé au développement du vaccin contre la COVID-19 et remercie BioNTech pour sa confiance...

    Plus d'info
  • New at Diaclone! SARS-CoV-2 SPIKE GLYCOPROTEIN RBD VARIANTS
    Date de publication : 21/01/2021
  • New at Diaclone - SARS-CoV-2 ELISA set
    Date de publication : 24/11/2020

    Diaclone continues to innovate and provide you with new research tools.

    Build your own serological assay with our new SARS-CoV-2 ELISA set.
    Contact Diaclone for more information...

    Plus d'info
  • Discover Diaclone's IL-1 Beta Monoclonal Antibody product range....
    Date de publication : 20/11/2020

    Diaclone have developed IL-1β monoclonal antibodies (the B-A15 clone, biologically active form) and immunoassays (ELISA and ELISpot kits) to help you monitor the immune responses to diverse...

    Plus d'info
  • Trail, the new Grail?
    Date de publication : 20/11/2020

    Diaclone has developed its TRAIL portfolio offering cytometry reagents, biologically active antibodies as well as kits for the determination of soluble forms of TRAIL and TRAIL receptors. Diaclone...

    Plus d'info
  • HEK293: when the virus meets the cell...
    Date de publication : 20/11/2020

    All you need to know about HEK293 cells...

    And you, are you currently working on recombinant protein expression?

    Do you need a helping hand with the viral transfection of HEK293?

    Read more...

    Plus d'info
  • NEW AT DIACLONE!... RECOMBINANT HUMAN SARS-CoV-2 PROTEINS
    Date de publication : 15/10/2020
    Developed in our laboratories in France   Plus d'info
  • Covid-19 Toolbox of the mAbexperts group
    Date de publication : 05/08/2020
  • Anti-S1 Domain Spike Protein is now available at Diaclone
    Date de publication : 03/08/2020


    Ideal for your COVID-19 studies...

    The antibody Anti-SARS-CoV-2 Spike S1 Protein CR3022 recognizes the S1 domain of the SARS-CoV Spike protein (aa318-510) as well as SARS-CoV-2 (COVID-19)...

    Plus d'info
  • IL1RAP, a therapeutic target for oncologic treatment
    Date de publication : 31/07/2020

    IL1-RAP, has been identified as a marker of interest in the context of CML treatments, activating NK cells and blocking tumour growth at the same time. Diaclone and Inserm teams  have been able...

    Plus d'info
  • Do you know the real potential of AAV?
    Date de publication : 01/07/2020

    Revealing the full potential of Adeno Associated Virus thanks to molecular biology

    Adeno-associated virus (AAV) is a small and single-strand DNA virus. In 1960, this non-enveloped entity was...

    Plus d'info
  • What you need to know about Exosomes
    Date de publication : 01/07/2020

    “Huge opportunities”. “Many hurdles”. “Enormous potential”...

    It's just an excerpt of the several terms you'll come across if you search for them on the...

    Plus d'info
  • Complete Proteome of COVID-19
    Date de publication : 15/06/2020

    Are you familiar with all the proteins of SARS-CoV-2?

    Read more on Linked In

    Are you working on any of these proteins?

    Which one would you like to see developed and validated?

    Contact...

    Plus d'info
  • RD-Biotech fournisseur des anticorps monoclonaux murins D1-25 et 1112-1, pour la quantification par ELISA de la glycoprotéine G du virus de la rage
    Date de publication : 15/06/2020

    Signature d’accord de licence avec Institut Pasteur (France) et le Winstar Institute (USA) permettant à RD-Biotech de commercialiser les 2 anticorps monoclonaux murins D1-25 et 1112-1...

    Plus d'info
  • Patients’ Immune Battle Against COVID-19
    Date de publication : 27/05/2020

    A brief review of the expected complications of CovId-19 infection.

    Read more on Linked In

    Diaclone offers a specific range of Antibodies, ELISA and ELISpot kits for COVID-19 research that can...

    Plus d'info
  • Fast track your Covid-19 Research with Diaclone’s CYTOKINES
    Date de publication : 26/05/2020

    Diaclone manufactures essential tools for Cytokine Storm monitoring & Immunotherapy...

    Plus d'info
  • RD-Biotech : Here to help you in your Covid-19 related research projects
    Date de publication : 28/04/2020
  • Essential tools for COVID-19 and Immunotherapy research
    Date de publication : 03/04/2020
  • depistage
    RD-BIOTECH produit les anticorps monoclonaux pour le test de dépistage de COVID-19 « Ag Respi-Strip » développé par CorisBioConcept !
    Date de publication : 03/04/2020

    RD-BIOTECH, acteur majeur en France dans la production d’anticorps monoclonaux et de protéines recombinantes est partenaire de la société belge Coris...

    Plus d'info
  • Future
    The Future of Therapeutic Antibody Development
    Date de publication : 12/03/2020

    The mAbexperts team has developed strong expertise in molecular biology to help you generate new formats of monoclonal antibodies.

    Read more on LinkedIn



     

    mAbexperts is a group...

    Plus d'info
  • Antibody Humanization
    Date de publication : 05/03/2020

    Many articles about antibodies refer to the term “humanization”.  

    But what does humanization mean? What technical approaches are used to carry out such a process? What are the...

    Plus d'info
  • Diaclone est partenaire d’un projet européen d’envergure associant une douzaine de partenaires de la région de Besançon
    Date de publication : 21/08/2018

    Le Projet MiMédi

    MIMEDI: MIcrotechnique pour les MEDicaments Innovants nouvelles solutions technologiques pour optimiser la fabrication de "cellules médicaments"

    Au sein...

    Plus d'info